With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of ...

2025 is not just another year in pharma – it’s a turning point. The industry is riding a wave of scientific breakthroughs, regulatory agility and patient-centric innovation that’s reshaping the very ...

Rebuilding the clinical trials landscape in the UK ...

Women’s health issues have historically been under-researched, marginalised and underserved. This systemic neglect has led to ...

MND isn’t incurable, it’s underfunded ...

More than half the UK population will experience a skin condition at some point in their lives. For many, these are debilitating diseases that can impact quality of life, mental health and daily ...

What is, exactly, going on with the NHS at the moment? You could be forgiven for thinking the fireworks of this summer’s ...

The rise of specialty and rare and orphan disease treatments, along with the increasing importance of patient-centricity, are driving the growth and heightened focus on hub services within US ...